Nasomucosa comprised mucosa, epithelia, columnar cells with transfer hair, microvillus cells, goblet cells, basal membrane and intestinal tissues. The nose has physiological and protective functions. IgA excreted by plasma cells in the mucosal intestinal membrane, neutralizes the soluble endotoxins of microbial, precipitates the microbial and fungus and prevent bacterial from nasomucosa. The low level IgA indicated that the nose is being suffered a disease. The nosedrops or aerosol must have fair pH
Immunity, Mucosal ; Mucous Membrane ; Immunoglobulin A

No abstract available.
Animals ; Humans ; *Immunity, Mucosal ; Vaccines/*immunology

It is a radical technique. With delicate modified instruments, this technique can improve considerably the function because of the advances in technology that emphasize mucosal preservation
Vocal Cords ; Immunity, Mucosal ; surgery ; Laryngeal Diseases

Vaccination is the most successful immunological practice that improves the quality of human life and health. Vaccine materials include antigens of pathogens and adjuvants potentiating the effectiveness of vaccination. Vaccines are categorized using various criteria, including the vaccination material used and the method of administration. Traditionally, vaccines have been injected via needles. However, given that most pathogens first infect mucosal surfaces, there is increasing interest in the establishment of protective mucosal immunity, achieved by vaccination via mucosal routes. This review summarizes recent developments in mucosal vaccines and their associated adjuvants.
Humans ; Immunity, Mucosal ; Methods ; Needles ; Vaccination ; Vaccines*

Mucosal vaccination, capable of inducing protective immune responses both in the mucosal and systemic immune compartments, has many advantages and is regarded as a blue ocean in the vaccine industry. Mucosal vaccines can offer lower costs, better accessability, needle-free delivery, and higher capacity of mass immunizations during pandemics. However, only very limited number of mucosal vaccines was approved for human use in the market yet. Generally, induction of immune responses following mucosal immunization requires the co-administration of appropriate adjuvants that can initiate and support the effective collaboration between innate and adaptive immunity. Classically, adjuvant researches were rather empirical than keenly scientific. However, during last several years, fundamental scientific achievements in innate immunity have been translated into the development of new mucosal adjuvants. This review focuses on recent developments in the concepts of adjuvants and innate immunity, mucosal immunity with special interest of vaccine development, and basic and applied researches in mucosal adjuvant.
Achievement ; Adaptive Immunity ; Cooperative Behavior ; Humans ; Immunity, Innate ; Immunity, Mucosal ; Immunization ; Mass Vaccination ; Pandemics ; Vaccination ; Vaccines

The mucosal surfaces are constantly exposed to incoming pathogens which can cause infections that result in severe morbidity and/or mortality. Studies have reported that mucosal immunity is important for providing protection against these pathogens and that mucosal vaccination is effective in preventing local infections. For many years, the sublingual mucosa has been targeted to deliver immunotherapy to treat allergic hypersensitivities. However, the potential of vaccine delivery via sublingual mucosal has received little attention until recently. Recent studies exploring such potential have documented the safety and effectiveness of sublingual immunization, demonstrating the ability of sublingual immunization to induce both systemic and mucosal immune responses against a variety of antigens, including soluble proteins, inter particulate antigens, and live-attenuated viruses. This review will summarize the recent findings that address the promising potential of sublingual immunization in proving protection against various mucosal pathogens.
Hypersensitivity ; Immunity, Mucosal ; Immunization ; Immunotherapy ; Mucous Membrane ; Proteins ; Vaccination ; Vaccines

OBJECTIVETo explore the regulative action of acupuncture and moxibustion on mucosal immunity and its curative effect on mucosal relative diseases.

METHODSReview the recent 10 years' achievements of studies on mucosal immunity and analyze the regulative action of acupuncture and moxibustion on the mucosal immunological system in treatment of mucosal relative diseases.

CONCLUSIONAcupuncture and moxibustion has a good regulative action on local mucosal immunological system, which is one of the mechanisms of acupuncture and moxibustion in prevention and treatment of mucosal relative diseases. This proves a more reliable basis for treatment of mucosal relative diseases with acupuncture and moxibustion.

OBJECTIVE: To investigate the age distribution characteristics of intestinal segmented filamentous bacteria (SFB) in children and their relationship with intestinal mucosal immunity. METHODS: The fresh feces of 177 children and the ileocecal fluid of 47 children during colonoscopy were collected. The SFB was determined by real-time PCR. The concentration of secretory immunoglobulin A (sIgA) was determined by enzyme-linked immunosorbent assay. The numbers of interleukin 17A (IL-17A) cells and intraepithelial lymphocytes in the terminal ileum mucosa and the expression of transcription factors associated with the differentiation of T helper (Th) cells, T-box transcription factor (T-bet), forkhead box P3 (FOXP3), and retinoid-related orphan receptor gamma t (ROR-γt), were determined by immunohistochemistry. RESULTS: The positive rate of intestinal SFB in these children was 19.2% (34/177). Trend analysis showed that the positive rate of SFB was correlated with age: the rates for children aged 0-, 1-, 2-, 3-, 4-, 5-, 6-, and 7-15 years were 40%, 47%, 32%, 15%, 12%, 13%, 15% and 4% respectively (P<0.001). The concentration of sIgA in intestinal fluid was significantly higher in SFB-positive children (n=24) than in SFB-negative children (n=23) (P<0.01). The number of intraepithelial lymphocytes in the terminal ileum mucosa and the expression of T-bet, FOXP3, and ROR-γt were not significantly different between the SFB-positive group (n=12) and the SFB-negative group (n=11), but the number of IL-17A cells in the terminal ileum mucosa was significantly lower in the SFB-positive group than in the SFB-negative group (P<0.05). CONCLUSIONS Intestinal SFB colonization in children is age-related, and the colonization rate is relatively high in children under 3 years old. In SFB-positive children, the secretion of intestinal sIgA is increased, while the number of IL-17A cells in the terminal ileum is reduced.
Adolescent ; Age Distribution ; Bacteria ; Child ; Humans ; Immunity, Mucosal ; Intestinal Mucosa

The mucosae represent the first line of defense against the invasion of most pathogens, and the mucosal immune system plays a crucial role in the control of infection. Mucosal vaccination can trigger both humoral and cell-mediated immune responses mucosally as well as systemically. Hence, protective immune responses can be elicited effectively by mucosal vaccination. Microfold (M) cells being unique to the mucosal immune system can take up luminal antigens and initiating antigen-specific immune responses. The number of antigen uptake by M cells is directly related to the immune efficacy of mucosal vaccines. Utilizing M cell ligands, M cells-targeting antigen delivery can achieve highly effective mucosal immune responses. The strategy of targeted delivery of antigens to M cells and its applications can be used for the improvement of mucosal immune responses and the development of mucosal vaccines. Despite these efforts, successful development of safe and effective mucosal vaccines remains a big challenge and needs a long way to go, and provably still resort to further researches on cellular properties and functions as well as mucosal immune mechanisms.
Immunity, Mucosal ; Ligands ; Mucous Membrane ; Vaccination ; Vaccines ; immunology

Development of a vaccine that can simultaneously induce effective mucosal immunity and systemic immunity is an ideal goal to prevent mucosal pathogenic infections. The digestive tract has many sites for inducing mucosal immunity, including the mouth, stomach and small intestine. An ideal oral viral vaccine can not only induce better local and distal mucosal immunity, but also produce better systemic immunity. The oral viral vaccine has also attracted much attention because of its painless vaccination, self-administration and other advantages. Due to the complexity of human digestive tract environment and mucosal immunity, only three oral attenuated live vaccines have been successfully marketed for human use. This review summarizes the characteristics of gastrointestinal mucosal immunity, the current types and research status of oral viral vaccines, and the challenges faced by oral viral vaccines, with the hope to facilitate the research and development of oral viral vaccines for human use in China.
Humans ; Viral Vaccines ; Vaccination ; Immunity, Mucosal ; Vaccines, Attenuated ; Vaccine Development